Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexion Pharmaceuticals’ ALXN1007 secures EU orphan drug status
The company is currently assessing ALXN1007 in patients with acute GVHD of the lower GI tract, a severe and life-threatening rare autoimmune disorder which can occur as a
The company is currently assessing ALXN1007 in patients with acute GVHD of the lower GI tract, a severe and life-threatening rare autoimmune disorder which can occur as a
Taigexyn is a novel antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria. Under the terms of the agreement, PC will be responsible for
The double-blind and placebo-controlled clinical study involving 40 healthy volunteers demonstrates the safety of topically applying FS2 cream at the maximum feasible dose with no adverse effects. The
The Company is issuing this press release to provide further heightened awareness of this recall and to provide instructions to consumers, pharmacists, and wholesalers in possession of the
Utilizing Ironshore’s proprietary delayed-release and extended-release technology, DELEXIS, HLD100 is intended for nighttime dosing and is designed to control ADHD symptoms and improve functioning immediately upon awakening and
The joint venture, named iPharma, will develop innovative clinical and pre-clinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets. Under the terms
Amgen is reviewing the Complete Response Letter, and we anticipate a post-action meeting with the FDA later this year to discuss the Complete Response. The Complete Response Letter
The trial was a multicenter, randomized, double-blind, multiple-dose, placebo-controlled study evaluating the efficacy and safety of three dosing regimens of Buprenorphine Sublingual Spray (0.5 mg three times daily
Imprime PGG acts as an immunological “ignition switch” enlisting the innate immune system to enhance the therapeutic efficacy of tumor targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. Under
The Company's SFX-01, a synthetic and stabilised version of sulforaphane, is currently in a Phase II trial, SAS (SFX-01 after Subarachnoid Haemorrhage), in the UK. The orphan drug